Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

68.71 +0.20 (+0.29%)
Streaming Delayed Price Updated: 11:45 AM EDT, Jun 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
84 85 Next >
Hims & Hers Takes Aim At Big Pharma In Controversial Super Bowl Ad — Retail Loves The Fight
The commercial aired Sunday night on Fox and positioned obesity as "America's deadliest epidemic" while criticizing the $160 billion weight-loss industry and the broader healthcare system. 
Via Stocktwits
NYSE:NVO is showing good growth, while it is not too expensive.
NYSE:NVO is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced. 
Via Chartmill
NVO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Novo Nordisk A/S Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action – NVO
From The Rosen Law Firm PA
Via GlobeNewswire
Is Novo Nordisk Stock a Buy Now?
Via The Motley Fool
What the Options Market Tells Us About Novo Nordisk
Via Benzinga
Earnings Scheduled For February 5, 2025
Via Benzinga
$100 Invested In Novo Nordisk 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Lowey Dannenberg Notifies Novo Nordisk A/S (“Novo” or the “Company”) (NYSE: NVO) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $200,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
IBD 50 Stock Hims & Hers Faces Backlash Over Provocative Super Bowl Ad
Shares rocketed on Friday, but the company might not be out of hot water yet. 
Via Investor's Business Daily
Novo Nordisk Eyes 2025 Regulatory Filing For Hemophilia Candidate After Encouraging Pediatric Study Data
Novo Nordisk's phase 3 trial of Mim8 in children with hemophilia A showed a 0.53 mean annualized bleeding rate, with 74.3% reporting zero treated bleeds. 
Via Benzinga
We Asked Retail Traders About Eli Lilly’s Biggest Post-Q4 Risk — Most Say It’s The Weight-Loss Drug Wars
Lilly’s fiercest competitor in the obesity market is Novo Nordisk, which offers Ozempic and Wegovy. However, rising threats from other players such as Hims & Hers, Amgen, and Viking Therapeutics also... 
Via Stocktwits
Mark Cuban Calls Out Elon Musk's Growing Influence Under Trump: 'On A Mission To Make Himself...Above And Beyond The President Of The United States'
Introduction: In a recent tweet, billionaire entrepreneur Mark Cuban raised questions about Elon Musk's intentions and his control over free speech, stirring a debate on the tech mogul's influence. 
Via Benzinga
Denmark Could Ban Or Push Ozempic, Wegovy And Shipping Prices Through The Roof If Trump Escalates Over Greenland
Via Benzinga
Topics Government
3 Cheap Growth Stocks You Can Buy for Less Than $100
Via The Motley Fool
Novo Nordisk Opposes 'Government Price Setting' As Elon Musk's DOGE Gains Access To CMS Amid Bernie Sanders' Criticism
Novo Nordisk said that its weight-loss drug Wegovy has reached 1.2 million U.S. patients, with 55 million individuals covered by insurance. 
Via Benzinga
Viking Therapeutics Plummeted 10% On Its Earnings Report. Here's Why.
Viking Therapeutics stock plunged late Wednesday on an earnings report that included mostly incremental updates. 
Via Investor's Business Daily
Why Novo Nordisk Stock Is Soaring Today
Via The Motley Fool
What To Expect When Eli Lilly Reports Q4 Earnings On Thursday?
Eli Lilly will announce Q4 2024 results, with analysts estimating $13.7 billion in sales and $4.94 EPS, alongside a revenue growth outlook for 2024. 
Via Benzinga
Novo Nordisk (NVO) Q4 2024 Earnings Call Transcript
NVO earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
Earnings Miss? Amgen’s Dividend Still a Bright Spot
Via MarketBeat
Novo Nordisk Stock Jumps On Q4 Beat: Retail Brushes Off Slower Growth Outlook To Chase Obesity Drug Boom
Barclays reportedly described the earnings as “good enough” to get Novo back on track. 
Via Stocktwits
Novo Nordisk Jumps After Ozempic Decidedly Beats. But 'Periodic Supply Constraints' Expected.
The company guided to 16% to 24% constant-currency sales growth in 2025. 
Via Investor's Business Daily
Novo Nordisk Q4 Earnings: Wegovy Sales More Than Double, Seeks Regulatory Approval For Hybrid Weight Loss Drug In 2026
Novo Nordisk reported Q4 sales of $11.96 billion, beating estimates. The company plans a new phase 3 trial for CagriSema in 2025, with results expected in Q1. 
Via Benzinga
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cardlytics, Novo Nordisk, Micron, and ModivCare and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Turnaround Tuesday - A Top 2025 Pick And A New Opportunity
Novo Nordisk recently had positive news on a trial about its impact on kidney disease, the stock then gapped up, and then sold off back to major support. 
Via Talk Markets
Topics Stocks / Equities
Novo Nordisk Stock Slides Before Q4 Earnings: Analysts Still See 68% Upside
Novo Nordisk (NVO) reports Q4 earnings with expectations of 86 cents EPS and $11.40B revenues. Stock down 29.55% YOY, 4.81% YTD. Analysts see 68% upside. 
Via Benzinga
Lowey Dannenberg Notifies Novo Nordisk A/S (“Novo” or the “Company”) (NYSE: NVO) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $200,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
From Faruqi & Faruqi LLP
Via GlobeNewswire
Novo Nordisk Faces Investor Concerns Over Hybrid CagriSema Trial Results For Weight Loss
Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors question trial protocols and transparency as Novo plans a new study. 
Via Benzinga
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
84 85 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.